Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026

Tempest Therapeutics, Inc.

100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.
Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.
Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.
Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-068614
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2026-02-25T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.390511+00:00
generated_at: 2026-05-16T00:16:46.031782+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-068614
json_url: https://secwatch.observer/filing/0001193125-26-068614.json
markdown_url: https://secwatch.observer/filing/0001193125-26-068614.md
text_url: https://secwatch.observer/filing/0001193125-26-068614.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/0001193125-26-068614-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/d22967d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-068614

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.